Diadema Partners LP Takes Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Diadema Partners LP acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 60,000 shares of the company's stock, valued at approximately $1,223,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank bought a new stake in Denali Therapeutics in the fourth quarter worth $21,717,000. Vanguard Group Inc. grew its stake in shares of Denali Therapeutics by 7.6% in the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock worth $244,993,000 after buying an additional 843,996 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Denali Therapeutics by 19.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock worth $37,805,000 after buying an additional 295,594 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Denali Therapeutics during the 4th quarter valued at about $5,891,000. Finally, Alliancebernstein L.P. lifted its holdings in shares of Denali Therapeutics by 8.8% in the 4th quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock valued at $67,573,000 after acquiring an additional 268,378 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on DNLI shares. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. B. Riley reissued a "buy" rating and set a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Morgan Stanley initiated coverage on Denali Therapeutics in a research report on Friday, March 7th. They issued an "overweight" rating and a $33.00 price target for the company. Robert W. Baird assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price objective for the company. Finally, Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Denali Therapeutics has an average rating of "Buy" and a consensus price target of $37.57.

Denali Therapeutics Trading Up 1.2 %

Shares of Denali Therapeutics stock traded up $0.19 during trading on Friday, hitting $15.68. 1,150,314 shares of the stock traded hands, compared to its average volume of 1,078,802. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The stock's fifty day simple moving average is $14.97 and its 200 day simple moving average is $20.87. The firm has a market cap of $2.28 billion, a P/E ratio of -5.68 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08. As a group, equities analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.